FTY720-C2

FTY720-C2 is a synthetic **small molecule analog of FTY720 (fingolimod)**, designed to maintain the neuroprotective and **protein phosphatase 2A (PP2A) stimulatory** properties of FTY720, while significantly reducing immunosuppressive effects. In preclinical studies, FTY720-C2 crosses the blood-brain barrier, increases brain-derived neurotrophic factor (BDNF) expression, counters TNF-α-induced toxicity in neuronal cells, and robustly stimulates PP2A activity in the adrenal gland and brain. Unlike parent FTY720, FTY720-C2 **does not undergo phosphorylation** in hepatocytes and therefore does not induce FTY720-like lymphopenia (a profound reduction in lymphocyte count), suggesting it lacks the immunosuppressive risk inherent to FTY720. FTY720-C2 is bioavailable by both oral and intravenous routes in animal studies, with rapid brain uptake and higher potency for stimulating PP2A than either FTY720 or other FTY720 analogs tested. FTY720-C2 is under preclinical evaluation for the treatment of neurodegenerative disorders such as Parkinson's disease[1][5][2].

Other names

FTY720-C2FTY-720-C2FTY 720-C2